menu
    • menu
    [{"orgOrder":0,"company":"Ascidian Therapeutics","sponsor":"Apple Tree Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Ascidian Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Ascidian Therapeutics \/ Apple Tree Partners","highestDevelopmentStatusID":"5","companyTruncated":"Ascidian Therapeutics \/ Apple Tree Partners"},{"orgOrder":0,"company":"Ascidian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"ACDN-01","moa":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Ascidian Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascidian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Ascidian Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ascidian Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"RNA-based Therapy","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Ascidian Therapeutics","amount2":1.8400000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":1.8400000000000001,"dosageForm":"","sponsorNew":"Ascidian Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"3","companyTruncated":"Ascidian Therapeutics \/ F. Hoffmann-La Roche"}]

    Find Clinical Drug Pipeline Developments & Deals by Ascidian Therapeutics

    Menu

    Ascidian Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ascidian Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Ascidian Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RNA-based Therapy

                            Therapeutic Area : Neurology

                            Study Phase : Discovery Platform

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : $1,842.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            TECVAYLI® Biweekly Dosing Approved by U.S. FDA for Relapsed or Refractory Multiple Myeloma

                            Details : Ascidian will provide Roche exclusive, target-specific rights to Ascidian's RNA exon editing technology for undisclosed neurological targets and will conduct discovery and preclinical activities.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : $42.0 million

                            June 18, 2024

                            Lead Product(s) : RNA-based Therapy

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery Platform

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : $1,842.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ascidian Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Ascidian Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ACDN-01

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ascidian Receives FDA Approval for ACDN-01 Trial in Stargardt's and ABCA4 Retinopathies

                            Details : ACDN-01 is the first-ever clinical-stage RNA exon editor, which is being evaluated in preclinical studies for the treatment of Stargardt disease & ABCA4 retinopathies.

                            Brand Name : ACDN-01

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 29, 2024

                            Lead Product(s) : ACDN-01

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ascidian Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Ascidian Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : Apple Tree Partners

                            Deal Size : $40.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Ascidian Therapeutics Raises $40 Million in Series A Extension Financing from Apple Tree Partners and Appoints...

                            Details : The funds will be used to advance Ascidian's lead program, an RNA exon editor to halt the progression of Stargardt disease or other ABCA4 retinopathies, and additional programs in the company's pipeline.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            November 08, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : Apple Tree Partners

                            Deal Size : $40.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth